PDT Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

PDT Partners’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-180,628	Closed	-$2.25M	–	496
2026 Q1	$2.25M	Hold	180,628	–	–	0.13%	230
2025 Q4	$2.28M	Hold	180,628	–	–	0.15%	229
2025 Q3	$1.81M	Sell	180,628 -46,363	-20%	-$416K	0.11%	274
2025 Q2	$1.84M	Sell	226,991 -11,078	-5%	-$83.5K	0.1%	319
2025 Q1	$2M	Buy	238,069 +158,900	+201%	+$1.33M	0.14%	252
2024 Q4	$627K	Buy	+79,169	New	+$664K	0.06%	432
2023 Q4	–	Sell	-88,008	Closed	-$371K	–	537
2023 Q3	$371K	Buy	+88,008	New	+$328K	0.05%	449
2022 Q4	–	Sell	-68,449	Closed	-$138K	–	624
2022 Q3	$138K	Sell	68,449 -61,681	-47%	-$173K	0.02%	762
2022 Q2	$414K	Sell	130,130 -6,686	-5%	-$24.2K	0.04%	645
2022 Q1	$571K	Buy	136,816 +26,250	+24%	+$116K	0.05%	540
2021 Q4	$530K	Buy	+110,566	New	+$551K	0.04%	512
2021 Q3	–	Sell	-36,020	Closed	-$184K	–	765
2021 Q2	$184K	Buy	+36,020	New	+$205K	0.01%	717

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

PDT Partners's AMRX Position: Q2 2026 in Review

PDT Partners sold out of Amneal Pharmaceuticals (AMRX) in Q2 2026, closing a stake of 180,628 shares — an estimated $2.25M sold.

PDT Partners first reported a position in AMRX in Q2 2021 and held it in 12 quarters. The position peaked at $2.28M in Q4 2025. 310 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

PDT Partners reported no remaining Amneal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
PDT Partners sold 180,628 Amneal Pharmaceuticals shares in Q2 2026, an estimated $2.25M.
PDT Partners first reported a position in Amneal Pharmaceuticals in Q2 2021 and held it in 12 quarters.
PDT Partners's Amneal Pharmaceuticals position peaked at $2.28M in Q4 2025.
310 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.